KDM7A and breast cancer: KDM7A can upregulate AR transcription activity via demethylating H3K27me2, and KDM7A inhibitor TC-E 5002 can significantly reduce cell viability in cisplatin-resistant bladder cancer cell lines.336 PHF8, also named KDM7B, can enhance the expression of FOXA2, which is essential for the development of neuroendocrine prostate cancer (NEPC) through demethylation modification (Table 3).337 Besides, PHF8 and HER2 can interact with each other in breast cancer, thus promoting the resistance to trastuzumab and other anti-HER2 drugs by regulating the expression of IL6 (Fig. 11).338